Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | TTK | P33981 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 11/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954965 | 0.89 | AURKA (0.55) | AURKAAURKBPDPK1CHEK1SRC | |
| SCHEMBL4897694 | 0.89 | AURKA (0.52) | AURKAAURKBPDPK1CHEK1SRC | |
| SCHEMBL4893017 | 0.88 | AURKA (0.47) | AURKAAURKBTTKPDPK1CDK2 | |
| SCHEMBL4893240 | 0.87 | AURKA (0.49) | AURKAAURKBPDPK1FLT3 | |
| SCHEMBL5191547 | 0.87 | AURKA (0.52) | AURKAAURKBPDPK1CHEK1KDR | |
| SCHEMBL4895975 | 0.86 | AURKA (0.48) | AURKAAURKBPDPK1CHEK1KDR | |
| SCHEMBL4893595 | 0.84 | AURKA (0.51) | AURKAAURKBTTKPDPK1CHEK1 | |
| SCHEMBL5188936 | 0.84 | AURKA (0.52) | AURKAAURKBPDPK1CHEK1FLT3 | |
| SCHEMBL4889092 | 0.83 | AURKA (0.49) | AURKAAURKBPDPK1CHEK1LRRK2 | |
| SCHEMBL5190146 | 0.83 | AURKA (0.55) | AURKAAURKBPDPK1CHEK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142247-A1 | Tricyclic heterocycles | HOFFMANN-LA ROCHE INC. | 2006-06-29 | — | — | US | claimed |
| EP-1831224-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142247-A1 | Tricyclic heterocycles | HOFFMANN-LA ROCHE INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063841-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142247-A1 | Tricyclic heterocycles | CYP11B1, CYP11B2, CYP3A43 | AURKA 2529/4885AURKB 2155/4885TTK 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.